Riskpilot← Back to searchSign inGet full accessVifor Pharma Nordiska AB
ABActiveOrg 5567393508Gustav Iii:S Boulevard 46Wholesale of pharmaceutical and medical goods · NACE 4646Est. 200734 employees
Revenue 2025
SEK 319,2M
-3% vs 2024
EBITDA margin
4.0%
-52% vs 2024
Equity ratio
23.2%
Financial strength
Net profit 2025
SEK 9,3M
-55% vs 2024
| Revenue | SEK 319,2M | -3% |
| EBITDA | SEK 12,6M | -52% |
| Net profit | SEK 9,3M | -55% |
| Total assets | SEK 329,5M | -13% |
| Equity | SEK 76,5M | +14% |
| Employees | 34 | — |
Legal name
Vifor Pharma Nordiska AB
Org number
5567393508
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
4 oktober 2007
Share capital
SEK 200 000
Employees
34 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamoten externa firmatecknarna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall bedriva utveckling,forskning och försäljning av läkemedel samt därmed förenlig verksamhet.
Address
Gustav Iii:S Boulevard 46
Phone
+46855806600
Email
info.nordic@viforpharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 225 847 | 243 890 | 434 633 | 330 221 | 319 183 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 6 058 | 8 094 | 9 518 | 26 222 | 12 618 |
| Depreciation & amort. | −225 | −203 | −285 | −182 | −89 |
| EBIT | 5 833 | 7 891 | 9 233 | 26 040 | 12 529 |
| Net financials | −99 | −726 | −1 386 | 125 | −54 |
| Profit before tax | 5 733 | 7 164 | 7 848 | 26 220 | 12 475 |
| Tax | −1 744 | −2 039 | −2 141 | −5 683 | −3 161 |
| Net profit | 3 989 | 5 125 | 5 707 | 20 537 | 9 314 |
| Item | 2020 | 2021 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 219 154 | 264 550 | 248 809 | 378 079 | 329 544 |
| Equity | 35 843 | 40 968 | 46 675 | 67 212 | 76 526 |
| Long-term debt | 6 100 | 115 000 | 115 000 | 115 000 | 115 000 |
| Short-term debt | 177 211 | 108 581 | 87 134 | 195 867 | 138 018 |
| Total debt | 183 311 | 223 581 | 202 134 | 310 867 | 253 018 |
EBITDA margin
4.0%
This company
15.8%
Market median
-75% vs market
20202025
Equity ratio
23.2%
This company
38.2%
Market median
-39% vs market
20202025
Return on equity
12.2%
This company
18.4%
Market median
+34% vs market
20202025
Net profit margin
2.9%
This company
8.1%
Market median
-64% vs market
20202025
Asset turnover
0.97×
This company
1.12×
Market median
+13% vs market
20202025
Debt / equity
3.31×
This company
0.62×
Market median
-434% vs market
20202025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-01-01 – 2023-06-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (8) | ||
HE Chief Executive Officer | Chief Executive Officer | 2026 |
PG Chief Auditor | Chief Auditor | 2020 |
AB External Signatory | External Signatory | 2020 |
BY External Signatory | External Signatory | 2022 |
SS External Signatory | External Signatory | 2022 |
BA External Signatory | External Signatory | 2026 |
DB External Signatory | External Signatory | 2020 |
CJ External Signatory | External Signatory | 2026 |
| Former (7) | ||
EA Chief Executive Officer | Chief Executive Officer | 2024 – 2025 |
AJ External Signatory | External Signatory | 2020 – 2021 |
EA Chief Executive Officer | Chief Executive Officer | 2025 – 2026 |
LA External Signatory | External Signatory | 2020 – 2025 |
LJ External Signatory | External Signatory | 2020 – 2022 |
HM External Signatory | External Signatory | 2021 – 2026 |
EM External Signatory | External Signatory | 2020 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2026 | |
| Deputy Board Member | 2026 | |
| Former (4) | ||
| Board of Directors | 2020 – 2026 | |
| Board of Directors | 2024 – 2026 | |
| Board of Directors | 2020 – 2020 | |
| Board of Directors | 2020 – 2024 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
VIFOR PHARMA PARTICIPATIONS AG
Vifor Pharma Nordiska AB (this company)Board members of Vifor Pharma Nordiska AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Eddy Atoine Bachir | Chief Executive Officer | 0 companies |
| Helena Elisabeth Gomér Bragd | Chief Executive Officer | 0 companies |
| Per Gustaf Hammar | Chief Auditor | 0 companies |
| António José Lorena de oliveira Jordão | External Signatory | 0 companies |
| Anna Birgitta Juhlin | External Signatory | 0 companies |
| Eddy Antoine Bachir | Chief Executive Officer | 0 companies |
| Leif Arne Lohm | External Signatory | 0 companies |
| Lars Jonas Lundmark | External Signatory | 0 companies |
| Britt Yvonne Thomson | External Signatory | 0 companies |
| Simon Stoffel | External Signatory | 0 companies |
| Björn Axel Grenfors | External Signatory | 0 companies |
| Hans Martin Bergman | External Signatory | 0 companies |
| David Bengt Colmander | External Signatory | 0 companies |
| Carl Johan Christer Werner | External Signatory | 0 companies |
| Ellen Maria Lohm | External Signatory | 0 companies |
| Marco Julius Walter Windisch | Board of Directors | 0 companies |
| Luis Rodolfo Birbuet | Board of Directors | 0 companies |
| Camilla Gyulshen Bilialovna Shen | Board of Directors | 0 companies |
| Alexandros Sigalas | Deputy Board Member | 0 companies |
| Michael Johann Walter Pröschel | Board of Directors | 0 companies |
| Ester Leris Casulleras | Board of Directors | 0 companies |